Search Results

CYTOO and Astellas Gene Therapies entered into a research collaboration in 2020 to select AGT’s AAV gene therapy clinical candidate to treat Duchenne Muscular Dystrophy.

Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced a collaboration with CYTOO aimed at informing the development of new AXA Candidates by leveraging CYTOO’s MyoScreenTM muscle-on-a-plate platform.

CYTOO, a leading drug discovery company on muscle disorders, today announced that it has entered into a research collaboration aimed at selecting a gene therapy candidate for a rare muscle disorder with Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage, fully integrated adeno-associated virus (AAV) gene therapy company.

Evozyne inked a partnership with Takeda Pharmaceutical to develop next-generation gene therapies for up to four rare disease targets. Continue reading for that and more collaboration news from this week.